Latest news

Proposal for New Stock Option Program Withdrawn

31 May, 2022

The board of directors of Nanologica AB (publ) has decided to withdraw the proposal for a new stock option program for management and employees that was presented in the notice to Nanologica’s Annual General Meeting on June 2, 2022. The board of directors has decided to withdraw the proposal to await the outcome of the stock option programs that expire on July 1 this year. Depending on the outcome, a new stock option program may

Förslag om nytt optionsprogram återkallas

31 May, 2022

Styrelsen för Nanologica AB (publ) har beslutat att återkalla det förslag om ett nytt optionsprogram för ledning och anställda som presenterades i kallelsen till Nanologicas årsstämma den 2 juni 2022. Styrelsen har beslutat att återkalla förslaget för att invänta utfallet av de optionsprogram som löper ut den 1 juli i år. Beroende på utfallet kan ett nytt optionsprogram komma att föreslås senare i år. “Vi vill uppmuntra till ett brett ägarskap bland ledning och anställda

CEO Andreas Bhagwani presenting At Naventus Healthcare Summit May 10, 2022

11 May, 2022

CEO Comment Q1 2022

9 May, 2022

A NEW CHAPTER BEGINS On March 29, 2022, a new chapter in Nanologica’s history began – as listed on a regulated market. By listing the share on Nasdaq Stockholm Main Market, we get an increased exposure and a better opportunity to attract institutional and international owners. At the same time, we are now launching our products for preparative chromatography. The big event of the quarter was the change of lists to Nasdaq Stockholm Main Market,

Introducing NLAB Saga®- a new generation silica for preparative chromatography

9 May, 2022

We are officially launching NLAB Saga® – Nanologica’s silica for preparative chromatography! NLAB Saga was developed with a clear goal in mind – to increase the availability of better and cheaper peptide and oligonucleotide-based medicines to a larger number of patients across the world, for the betterment of mankind. NLAB Saga has been specifically developed to meet the strict requirements of industrial scale purification by chromatography. Due to its exceptional mechanical and chemical stability, NLAB

Kallelse till årsstämma i Nanologica AB (publ)

4 May, 2022

Aktieägarna i Nanologica AB (publ), org.nr 556664-5023 (”Bolaget”) kallas härmed till årsstämma torsdagen den 2 juni 2022, klockan 12.00, i The Parks lokaler på Magnus Ladulåsgatan 1, Stockholm. Rätt att delta vid stämman Aktieägare som önskar delta i årsstämman ska: dels vara registrerad i eget namn (inte förvaltarregistrerad) i den av Euroclear Sweden AB förda aktieboken tisdagen den 24 maj 2022, dels anmäla sitt deltagande så att anmälan är Bolaget tillhanda senast måndagen den 30

About us

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.

Categories

News archive